1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,626 | 0,656 | 17:45 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.12.25 | Cereno Scientific's Board of Directors and Management Enter Lock-up Agreements | 1 | Cision News | ||
| 18.12.25 | Cereno Scientific to Host Capital Markets Day on February 5, 2026 | 2 | Cision News | ||
| 11.12.25 | Cereno Scientific - Runway clears for Phase IIb with FDA nod | 251 | Edison Investment Research | Cereno Scientific has announced that it has been granted FDA clearance for its global Phase IIb trial for CS1 in pulmonary arterial hypertension (PAH), clearing the way for trial initiation in Q226.... ► Artikel lesen | |
| 08.12.25 | Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH) | 321 | PR Newswire | GOTHENBURG, Sweden, Dec. 8, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 03.12.25 | Cereno Scientific to Present New Data of CS014 at the Pharmacology 2025 on December 15-18 | 1 | Cision News | ||
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 02.12.25 | Cereno Scientific - Armed and ready for Phase II | 310 | Edison Investment Research | Cereno Scientific reported its Q325 results, a quarter focused on Phase II preparations for lead assets CS1 and CS014, following encouraging Phase I data for CS014, fast track designation for CS1 and... ► Artikel lesen | |
| 30.11.25 | Correction: Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027 | 1 | Cision News | ||
| 28.11.25 | Cereno Scientific AB: Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027 | 180 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen | |
| 28.11.25 | Cereno Scientific AB: Cereno Scientific: Major shareholders and new investors back the Company's long-term strategy with equity investment at a premium | 158 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B) (the "Company"), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announced... ► Artikel lesen | |
| 27.11.25 | Cereno Scientific AB Loss At -SEK21.32 Mln In Q3 | - | RTTNews | ||
| 27.11.25 | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q3 2025 (July 1 - September 30, 2025) | 238 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 10.11.25 | Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. FDA | 288 | PR Newswire | GOTHENBURG, Sweden, Nov. 10, 2025 /PRNewswire/ -- Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people... ► Artikel lesen | |
| 24.09.25 | Cereno Scientific Participates at Partnering and Investor Conference Nordic Life Science Days 2025 | 1 | Cision News | ||
| 15.09.25 | Cereno Scientific Announces Conversion of All Remaining Convertibles Following Request by Fenja Capital II A/S and Arena Investors, LP | 1 | Cision News | ||
| 03.09.25 | Cereno Scientific Announces Sten R. Sörensen Named Finalist for 'CEO of the Year' at the European Lifestars Awards 2025 | 1 | Cision News | ||
| 02.09.25 | Cereno Scientific Participates at GoCo Investor Day on September 9, 2025, in Gothenburg | 1 | Cision News | ||
| 27.08.25 | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q2 2025 (April 1 - June 30, 2025) | 777 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 26.08.25 | Cereno Scientific AB: Cereno Scientific Granted FDA Fast Track Designation for CS1 in Rare Disease Pulmonary Arterial Hypertension (PAH) | 576 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 06.08.25 | Cereno Scientific announces conversion of convertibles following request by Fenja Capital II A/S and Arena Investors, LP | 2 | Cision News | ||
| 17.07.25 | Cereno Scientific - Phase II calling for CS014 after Phase I success | 441 | Edison Investment Research | Cereno Scientific reported positive Phase I readouts for CS014, its novel HDAC inhibitor, paving the way for Phase II studies in idiopathic pulmonary fibrosis (IPF). The candidate demonstrated favourable... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,405 | -1,16 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| BIONTECH | 82,45 | +1,35 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,01 | -0,17 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| EVOTEC | 5,533 | +1,52 % | Evotec-Aktie: Könnte schon bald die 0 Euro vorm Kurs stehen? | © Foto: fn SymbolbildDer Hamburger Biotech-Konzern Evotec taumelt. Die Aktie notiert noch knapp über der 5-Euro-Marke, aber nur wenige Cent vom Jahrestief entfernt. Gleichzeitig verkauft der Forschungsvorstand... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,870 | -0,59 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 74,40 | -1,42 % | BTIG bestätigt Kaufempfehlung für Apogee Therapeutics angesichts positiver Aussichten | ||
| RECURSION PHARMACEUTICALS | 4,215 | +3,06 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| STRUCTURE THERAPEUTICS | 67,86 | -2,51 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,530 | -4,13 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,020 | -1,41 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 73,06 | -6,10 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 286,51 | -3,02 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor | The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA... ► Artikel lesen | |
| IMMUNOME | 20,535 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| TARSUS PHARMACEUTICALS | 80,75 | -1,38 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| CG ONCOLOGY | 41,280 | -0,63 % | CG Oncology Inc.: CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates | Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated... ► Artikel lesen |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,63 % bei einem Aktienkurs von 0,631 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.